Key result
Longer time elapsed from symptom onset to Alzheimer's disease diagnosis was associated with an increased probability of antipsychotic consumption (overall CNS drug consumption was 95.8%).
Why the study?
Does a longer time from symptom onset to Alzheimer's disease diagnosis increase the consumption of central nervous system drugs in patients with Alzheimer's disease?
Cross-Sectional (n=952)
Does a longer time from symptom onset to Alzheimer's disease diagnosis increase the consumption of central nervous system drugs in patients with Alzheimer's disease?
A longer delay between symptom onset and Alzheimer's disease diagnosis is associated with an increased probability of antipsychotic consumption.
Diagnostic delays in AD may heighten antipsychotic exposure; hypothesis-generating for earlier diagnosis reducing CNS drug burden.
AIMS: To describe central nervous system (CNS) drug consumption patterns depending on the time to diagnosis of Alzheimer's disease (AD), and to check whether the cases diagnosed later are associated with greater severity and consuming more CNS drugs. METHODS: Cross-sectional study using 952 cases of the Registry of Dementias of Girona. A binary logistic regression was used to detect variables associated with the use of CNS drugs depending on the time to diagnosis. RESULTS: CNS drugs were consumed by 95.8% of the AD patients. Only antipsychotics presented a statistically significant increase in the frequency of prescription to patients with longer time elapsed from symptom onset to AD diagnosis. CONCLUSION: Longer time elapsed from the onset of symptoms to the diagnosis resulted in increased probability of antipsychotic consumption.
No takes yet. Share an insight, caveat, or question.
Calvó‐Perxas et al. (2012) conducted a cross-sectional in Alzheimer's disease (n=952). Longer time elapsed from symptom onset to diagnosis vs. Shorter time elapsed from symptom onset to diagnosis was evaluated on Central nervous system drug consumption. Longer time elapsed from symptom onset to Alzheimer's disease diagnosis was associated with an increased probability of antipsychotic consumption (overall CNS drug consumption was 95.8%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: